Current therapies for primary SCLC include programmed cell death ligand 1 (PD-L1) inhibitors as the first line treatment, although anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibodies have also been shown to be effective against the disease [24,25,26]. The gene discussed is CD274; the disease is small cell lung carcinoma.